The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Nicotinamide Riboside Preserves Cardiac Function in a Mouse Model of Dilated Cardiomyopathy
Open accessAbstract
Background: Myocardial metabolic impairment is a major feature in chronic heart failure. As the major coenzyme in fuel oxidation and oxidative phosphorylation and a substrate for enzymes signaling energy stress and oxidative stress response, nicotinamide adenine dinucleotide (NAD + ) is emerging as a metabolic target in a number of diseases including heart failure. Little is known on the mechanisms regulating homeostasis of NAD + in the failing heart. Methods: To explore possible alterations of NAD + homeostasis in the failing heart, we quantified the expression of NAD + biosynthetic enzymes in the human failing heart and in the heart of a mouse model of dilated cardiomyopathy (DCM) triggered by Serum Response Factor transcription factor depletion in the heart (SRF HKO ) or of cardiac hypertrophy triggered by transverse aorta constriction. We studied the impact of NAD + precursor supplementation on cardiac function in both mouse models. Results: We observed a 30% loss in levels of NAD + in the murine failing heart of both DCM and transverse aorta constriction mice that was accompanied by a decrease in expression of the nicotinamide phosphoribosyltransferase enzyme that recycles the nicotinamide precursor, whereas the nicotinamide riboside kinase 2 (NMRK2) that phosphorylates the nicotinamide riboside precursor is increased, to a higher level in the DCM (40-fold) than in transverse aorta constriction (4-fold). This shift was also observed in human failing heart biopsies in comparison with nonfailing controls. We show that the Nmrk2 gene is an AMP-activated protein kinase and peroxisome proliferator-activated receptor α responsive gene that is activated by energy stress and NAD + depletion in isolated rat cardiomyocytes. Nicotinamide riboside efficiently rescues NAD + synthesis in response to FK866-mediated inhibition of nicotinamide phosphoribosyltransferase and stimulates glycolysis in cardiomyocytes. Accordingly, we show that nicotinamide riboside supplementation in food attenuates the development of heart failure in mice, more robustly in DCM, and partially after transverse aorta constriction, by stabilizing myocardial NAD + levels in the failing heart. Nicotinamide riboside treatment also robustly increases the myocardial levels of 3 metabolites, nicotinic acid adenine dinucleotide, methylnicotinamide, and N1-methyl-4-pyridone-5-carboxamide, that can be used as validation biomarkers for the treatment. Conclusions: The data show that nicotinamide riboside, the most energy-efficient among NAD precursors, could be useful for treatment of heart failure, notably in the context of DCM, a disease with few therapeutic options.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, they have demonstrated beneficial pharmacological activities in acute renal failure [28], anti-inflammatory [29–31], cardio and vasoprotective actions [32–35], telomere lengthening [36, 37•], extend lifespan and promote health in various organisms, from yeasts to mammals [10, 14, 15, 38].”
From NAD+ Precursors Nicotinamide Mononucleotide (NMN) and Nicotinamide Riboside (NR): Potential Dietary Contribution to Health (2023) · cites this paper as [35]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“NR (450 mg/kg body weight for 45 days) stabilized myocardial NAD+ levels, increased glycolysis, and citrate and acetyl-coenzyme A metabolism, attenuating the development of heart failure in a mouse model with dilated cardiomyopathy [35].”
From NAD+ Precursors Nicotinamide Mononucleotide (NMN) and Nicotinamide Riboside (NR): Potential Dietary Contribution to Health (2023) · cites this paper as [35]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ATP-citrate lyase links cellular metabolism to histone acetylation
Wellen, K. E., Hatzivassiliou, G., Sachdeva, U. M., Bui, T. V., Cross, J. R., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1164097 · Cited by 2,298
Cantó, C., Menzies, K. J., & Auwerx, J. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.05.023 · Cited by 1,648
Cantó, C., Houtkooper, R. H., Pirinen, E., Youn, D. Y., Oosterveer, M. H., Cen, Y., Fernandez-Marcos, P. J., Yamamoto, H., Andreux, P. A., Cettour-Rose, P., et al. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.04.022 · Cited by 1,238
Mouchiroud, L., Houtkooper, R. H., Moullan, N., Katsyuba, E., Ryu, D., Cantó, C., Mottis, A., Jo, Y.-S., Viswanathan, M., Schoonjans, K., et al. (2013) · Cell · doi:10.1016/j.cell.2013.06.016 · Cited by 1,210
NAD+ metabolism in health and disease
Belenky, P. A., Bogan, K. L., & Brenner, C. (2006) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2006.11.006 · Cited by 1,006
Self-citationBieganowski, P., & Brenner, C. (2004) · Cell · doi:10.1016/s0092-8674(04)00416-7 · Cited by 750
Self-citationBogan, K. L., & Brenner, C. (2008) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.28.061807.155443 · Cited by 707
Self-citationNicotinamide riboside is uniquely and orally bioavailable in mice and humans
Trammell, S. A. J., Schmidt, M. S., Weidemann, B. J., Redpath, P., Jaksch, F., Dellinger, R. W., Li, Z., Abel, E. D., Migaud, M. E., & Brenner, C. (2016) · Nature Communications · doi:10.1038/ncomms12948 · Cited by 697
Self-citationLund, L. H., Edwards, L. B., Kucheryavaya, A. Y., Benden, C., Dipchand, A. I., Goldfarb, S., Levvey, B. J., Meiser, B., Rossano, J. W., Yusen, R. D., et al. (2015) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2015.08.003 · Cited by 534
Lamin A/C and emerin regulate MKL1–SRF activity by modulating actin dynamics
Ho, C. Y., Jaalouk, D. E., Vartiainen, M. K., & Lammerding, J. (2013) · Nature · doi:10.1038/nature12105 · Cited by 456
Flagged first, then by citations
Cited by
Sorted by citations
Cardiac Energy Metabolism in Heart Failure
Lopaschuk, G. D., Karwi, Q. G., Tian, R., Wende, A. R., & Abel, E. D. (2021) · Circulation Research · doi:10.1161/circresaha.121.318241 · Cited by 1,458
Mitochondrial dysfunction in pathophysiology of heart failure
Zhou, B., & Tian, R. (2018) · Journal of Clinical Investigation · doi:10.1172/jci120849 · Cited by 973
Treating Oxidative Stress in Heart Failure: Past, Present and Future
van der Pol, A., van Gilst, W. H., Voors, A. A., & van der Meer, P. (2018) · European Journal of Heart Failure · doi:10.1002/ejhf.1320 · Cited by 838
Heart Failure in Type 2 Diabetes Mellitus
Kenny, H., & Abel, E. D. (2019) · Circulation Research · doi:10.1161/circresaha.118.311371 · Cited by 682
NAD+ homeostasis in health and disease
Katsyuba, E., Romani, M., Hofer, D., & Auwerx, J. (2020) · Nature Metabolism · doi:10.1038/s42255-019-0161-5 · Cited by 627
Metadata
- Authors
- Diguet, N., Trammell, S. A. J., Tannous, C., Deloux, R., Piquereau, J., Mougenot, N., Gouge, A., Gressette, M., Manoury, B., Blanc, J., Breton, M., Decaux, J.-F., Lavery, G. G., Baczkó, I., Zoll, J., Garnier, A., Li, Z., Brenner, C., & Mericskay, M.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- University of Iowa (US)
- Université Paris-Sud (FR)
- Inserm (FR)
- Sorbonne Université (FR)
- University of Birmingham (GB)
- University of Szeged (HU)
- Hôpital Lariboisière (FR)
- Corresponding author
- Tannous, Cynthia
- Deloux, Robin
- ORCID
- Venue
- Circulation
- Published
- 2018-05-22
- Volume
- 137
- Issue
- 21
- Pages
- 2256-2273
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- PMC
- PMC6954688
- OpenAlex
- W2775095764
- Cited by
- 358
- References
- 50
- Citations by year
- 2026: 28 · 2025: 42 · 2024: 49 · 2023: 47 · 2022: 57 · 2021: 47 · 2020: 49 · 2019: 24 · 2018: 12
- FWCI
- 14.21
- Type
- journal article
- Language
- en
- Update notices
- correction (2018-05-22)
- Open access
- bronze
- doi.org
- Locations
- Circulation (publishedVersion)
- PubMed (publishedVersion)
- SZTE Publicatio Repozitórium (University of Szeged) (acceptedVersion, other-oa)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- HAL (submittedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Funders
- Wellcome Trust (104612/Z/14/Z)
- Agence Nationale de la Recherche (ANR-08-GENO-0038, ANR-17-CE17-0015)
- Institut National de la Santé et de la Recherche Médicale
- Université de Strasbourg
- Centre National de la Recherche Scientifique
- Université Pierre et Marie Curie
- Université Paris-Saclay
- Szegedi Tudományegyetem
- Roy J. and Lucille A. Carver College of Medicine, University of Iowa
- National Institute of General Medical Sciences (T32GM008629)
- Topics
- Health Sciences › Medicine › Geriatrics and Gerontology › Sirtuins and Resveratrol in Medicine
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiomyopathy and Myosin Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Biochemical and Molecular Research
- Keywords
- nicotinamide riboside, NAD+ homeostasis, dilated cardiomyopathy, heart failure, NAD biosynthesis, visfatin, AMPK, PPARα, myocardial energy metabolism, glycolysis, transverse aortic constriction, cardiac hypertrophy, cardiomyocytes, NAD+ precursor supplementation, chronic heart failure
- MeSH terms
- Acrylamides, Animals, Cardiomyopathy, Dilated, Disease Models, Animal, Heart Failure, Mice, Transgenic, NAD, Niacinamide, Piperidines, Pyridinium Compounds, Cytokines, Phosphotransferases (Alcohol Group Acceptor), Citric Acid, Dietary Supplements, Gene Expression Profiling, Serum Response Factor, Myocytes, Cardiac, PPAR alpha, Mice, Rats, Nicotinamide Phosphoribosyltransferase, AMP-Activated Protein Kinases, Metabolome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
